 |
Partners' Directory |
| Home Search Join the Partnership Login | |
| Contact | General | Specializations in Countries | Contribution to the Global Plan | Declaration |
View this partner's profile
Organization Contact Information | |
| Name: | Genetix Biotech Asia Pvt. Ltd. |
| Street 1: | 71/1, First Floor |
| Street 2: | Nagargarh road, Shivaji Marg |
| City: | Delhi |
| Province: | Delhi |
| Post Code: | 110015 |
| Country: | India |
| Phone: | +91-11-45027000 |
| Organization Email: | info@genetixbiotech.com |
| Web Site: | http://genetixbiotech.com/ |
| Other Online Presence: | http://www.linkedin.com/company/genetix-biotech-asia-p-ltd./mycompany/ |
|
|
||||||||||||||||||||||||||||
General Information | |
| Board Constituency: | None |
| Is your organization legally registered in your country: | Yes |
| If yes, please enter your registration number: | U24239DL2001PTC112768 |
| Organization Type - Primary: | Private Sector |
| Organization Type - Secondary: | None |
| Organization Description: | |
| One of the main areas of concentration for Genetix Biotech Asia Pvt. Ltd., a prominent provider of healthcare and diagnostics, is R&D and innovation for the creation of molecular kits, fleet deployment, and healthcare solutions. We take great delight in offering the most cutting-edge and reasonably priced technology to the Indian life science, diagnostics, and healthcare markets in order to better serve the general public as well as businesses and research facilities. As the cornerstones of our business, diagnostics, life science products, bioprocessing, and medical technology and devices remain vital. One of the world's oldest illnesses is tuberculosis. In terms of both TB-related mortality and prevalence, India has the largest burden of TB. Individuals with HIV/AIDS who are on antiretroviral therapy are particularly vulnerable to TB-related problems. Furthermore, the number of pediatric TB cases is increasing, which poses significant obstacles to the National Strategy Plan for TB Elimination (NSP 2020–2025) and makes the National TB Elimination Program's ambitious goal of eliminating TB entirely from India by 2025 seem unrealistic. Treatment and eradication of tuberculosis are further threatened by drug-resistant strains of the disease. One of the most challenging forms of tuberculosis to identify is extensive drug resistance tuberculosis (XDR-TB), which is resistant to both first-line anti-TB medications (rifampicin and isoniazid) and second-line medications (fluoroquinolones) and second-line injectables (amikacin, capreomycin, kanamycin, etc.). The only test that can identify this type of variation is the Drug Susceptibility Test, which has several inherent limitations, including poor repeatability and reliability and a weeks-long turnaround time for results. With the help of Taqman probes, which are fluorescently tagged, Genetix Biotech offers a state-of-the-art point-of-care technology called GeneNAT 300 along with pre-loaded microchips that can detect XDR-TB with absolute specificity and sensit |
|
| Do you know about the UNHLM declaration: | Yes |
Specializations / Areas of Work | |
|
Delivery of health services and care Research and Development |
Other Organization Information | |
| Total number of staff in your organization: | 100 + |
| Number of full-time staff who are directly involved with TB: | 11 - 25 |
| Number of part-time staff who are directly involved with TB: | 1 - 5 |
| Number of volunteers who are directly involved with TB: | 0 |
| How did you hear about the Stop TB Partnership: | Stop TB communications |
| If you were informed or referred by another partner of the Stop TB Partnership please tell us who: | |
| Why do you wish join the Stop TB Partnership: | Involvement in Stop TB Working Groups |
| Are you a member of a Stop TB national partnership: | No |
| Are you in contact with your national TB programme: | Yes |
| Please tell us how your organization is contributing to your country's national TB control plan: | |
| With its POC platform GeneNAT 300/340, Genetix Biotech has played a key role in the development of drug-resistant variants and chip-based molecular detection of MTB. It provides a number of distinctive and essentially sonic features: 1. Early TB detection with little need for a sample. 2. Highly sensitive and specific molecular testing to identify tuberculosis. 3. A sturdy platform that requires little upkeep. 4. Quicker outcomes with less manual labor needed. 5. Its cost-effectiveness and smaller footprint make it appropriate for Proof of Concept implementation. 6. Reliable MDR and XDR TB case detection for an expedited treatment strategy. |
|
Geographical Reach | |
| Which country is your headquarters located in: | India |
| Which countries do you do operate in: (This includes countries you are conducting activities in) |
India |
Contribution | |
| Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: | |
|
TB Care Delivery: 1. Early detection of TB, even in subclinical cases. 2. Development of scientific and layman communication to raise awareness against TB among peers and the general population. 3. Monitoring doubtful TB cases. 4. Extending the application of real-time molecular TB screening and drug-resistant variant detection to determine an effective treatment plan and stop the disease's spread. Drug-Resistant TB: 1. Development of an MDR-TB detection kit to detect both Rifampicin and Isoniazid resistance at the same time within 40–50 minutes. 2. Development of XDR-TB kit for detection of fluoroquinolones and second-line injectable resistance at ease. 3. Highly reliable and robust tool that requires minimal maintenance and training. 4. It requires minimal hands-on time, making it error-proof. TB-HIV: Genetix Biotech is currently in the inception and development of HIV/MTB co-detection molecular kit compatible with Genetix' GeneNAT300/340 platform for the detection of TB in HIV patients. Laboratory Strengthening: We are steadily strengthening our manpower with more PhDs with sound experience in several molecular techniques, including the development of nucleic acid extraction, PCR, real-time PCR, troubleshooting techniques, and development. We have more than 15 PhDs constantly monitoring the TB scenario in India and the market needs in line with the Government of India's directives for the elimination of TB in India. We are aligning with GoI's TB program for quicker deployment of the tools to the periphery. Genetix' R & D lab is equipped with state-of-the-art facilities and instrument to assist in the development of new tools and kits. New Diagnostics: We are currently focusing on the development of XDR-TB detection kits and HIV/MTB simultaneous detection kits. Fundamental Research: Genetix Biotech is dedicated to conducting basic research and analyzing the needs of the tuberculosis market. The main goal of research is to match novel strains and mutations in the MTB genome with treatment resistance. Research: In addition to the TB threat, we are concentrating on the research and development of many molecular tests for the identification of various infectious and non-communicable diseases that afflict India. |
|
Declaration | |
| Declaration of interests: No conflicts of interest were delacred. | |
| Application date: | June 12, 2024 |
| Last updated: | July 2, 2024 |